BG106850A - ПИРИДО [2,3-d] ПИРИМИДИН - 2,7 - ДИАМИН КИНАЗА ИНХИБИТОРИ - Google Patents

ПИРИДО [2,3-d] ПИРИМИДИН - 2,7 - ДИАМИН КИНАЗА ИНХИБИТОРИ Download PDF

Info

Publication number: BG106850A
Authority: BG; Bulgaria
Prior art keywords: pyrimidin; pyrido; urea; piperazin; phenylamino
Prior art date: 2000-01-25

Application number

BG106850A

Other languages

Bulgarian (bg)

English (en)

Inventor

Richard Booth

Ellen Dobrusin

Vara Josyula

Dennis McNAMARA

Peter Toogood

Original Assignee

Warner-Lambert Company Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-25

Filing date

2002-06-20

Publication date

2003-02-28

2002-06-20 Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc

2003-02-28 Publication of BG106850A publication Critical patent/BG106850A/bg

Links

QRRCMVPZJCHBLQ-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine-2,7-diamine Chemical compound C1=NC(N)=NC2=NC(N)=CC=C21 QRRCMVPZJCHBLQ-UHFFFAOYSA-N 0.000 title description 2
229940043355 kinase inhibitor Drugs 0.000 title 1
239000003757 phosphotransferase inhibitor Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 147
125000000217 alkyl group Chemical group 0.000 claims abstract description 69
229910052736 halogen Inorganic materials 0.000 claims abstract description 56
239000001257 hydrogen Substances 0.000 claims abstract description 40
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 40
125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 37
125000001072 heteroaryl group Chemical group 0.000 claims abstract description 29
125000000623 heterocyclic group Chemical group 0.000 claims abstract description 28
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 28
125000003118 aryl group Chemical group 0.000 claims abstract description 27
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 23
125000003342 alkenyl group Chemical group 0.000 claims abstract description 21
125000000304 alkynyl group Chemical group 0.000 claims abstract description 21
206010028980 Neoplasm Diseases 0.000 claims abstract description 19
125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 18
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
201000011510 cancer Diseases 0.000 claims abstract description 13
239000003102 growth factor Substances 0.000 claims abstract description 12
230000002062 proliferating effect Effects 0.000 claims abstract description 11
230000001404 mediated effect Effects 0.000 claims abstract description 8
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
208000037803 restenosis Diseases 0.000 claims abstract description 8
-1 nitro, carboxy Chemical group 0.000 claims description 179
239000004202 carbamide Substances 0.000 claims description 61
150000002367 halogens Chemical class 0.000 claims description 54
238000000034 method Methods 0.000 claims description 39
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 31
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 26
125000003545 alkoxy group Chemical group 0.000 claims description 25
125000004663 dialkyl amino group Chemical group 0.000 claims description 23
102000004190 Enzymes Human genes 0.000 claims description 21
108090000790 Enzymes Proteins 0.000 claims description 21
101150073031 cdk2 gene Proteins 0.000 claims description 21
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 21
150000003839 salts Chemical class 0.000 claims description 21
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 19
150000002148 esters Chemical class 0.000 claims description 17
229910052757 nitrogen Inorganic materials 0.000 claims description 17
150000002431 hydrogen Chemical class 0.000 claims description 16
150000001408 amides Chemical class 0.000 claims description 15
229910052760 oxygen Inorganic materials 0.000 claims description 15
239000000651 prodrug Substances 0.000 claims description 15
229940002612 prodrug Drugs 0.000 claims description 15
102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 14
108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 14
125000002837 carbocyclic group Chemical group 0.000 claims description 12
230000002401 inhibitory effect Effects 0.000 claims description 12
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 12
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 11
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 11
125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims description 11
101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 claims description 10
125000003710 aryl alkyl group Chemical group 0.000 claims description 10
125000004181 carboxyalkyl group Chemical group 0.000 claims description 10
101150012716 CDK1 gene Proteins 0.000 claims description 9
101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 claims description 9
125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 9
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 9
239000001301 oxygen Substances 0.000 claims description 9
229910052717 sulfur Inorganic materials 0.000 claims description 9
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
208000035475 disorder Diseases 0.000 claims description 8
125000005842 heteroatom Chemical group 0.000 claims description 8
201000010099 disease Diseases 0.000 claims description 7
125000004446 heteroarylalkyl group Chemical group 0.000 claims description 7
125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
230000035755 proliferation Effects 0.000 claims description 6
201000001320 Atherosclerosis Diseases 0.000 claims description 5
201000004681 Psoriasis Diseases 0.000 claims description 5
239000003085 diluting agent Substances 0.000 claims description 5
210000002464 muscle smooth vascular Anatomy 0.000 claims description 5
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
VFDPUSVWSHRPRA-UHFFFAOYSA-N 1-cyclohexyl-3-[2-[4-(piperazine-1-carbonyl)anilino]pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound C=1C=C2C=NC(NC=3C=CC(=CC=3)C(=O)N3CCNCC3)=NC2=NC=1NC(=O)NC1CCCCC1 VFDPUSVWSHRPRA-UHFFFAOYSA-N 0.000 claims description 4
206010006187 Breast cancer Diseases 0.000 claims description 4
208000026310 Breast neoplasm Diseases 0.000 claims description 4
230000004663 cell proliferation Effects 0.000 claims description 4
210000001072 colon Anatomy 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
DWRWSNAREGLUHZ-UHFFFAOYSA-N ethyl pyrimidine-4-carboxylate Chemical compound CCOC(=O)C1=CC=NC=N1 DWRWSNAREGLUHZ-UHFFFAOYSA-N 0.000 claims description 4
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 3
125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 3
208000032839 leukemia Diseases 0.000 claims description 3
201000005202 lung cancer Diseases 0.000 claims description 3
208000020816 lung neoplasm Diseases 0.000 claims description 3
201000001441 melanoma Diseases 0.000 claims description 3
206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
XMINZZZOTRYZGB-UHFFFAOYSA-N 1-(2-hydroxyethyl)-3-[2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound N=1C2=NC(NC(=O)NCCO)=CC=C2C=NC=1NC(C=C1)=CC=C1N1CCNCC1 XMINZZZOTRYZGB-UHFFFAOYSA-N 0.000 claims description 2
XFILUMCRLWWGHF-UHFFFAOYSA-N 1-(2-hydroxyethyl)-3-[5-methyl-2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound N=1C=C2C(C)=CC(NC(=O)NCCO)=NC2=NC=1NC(C=C1)=CC=C1N1CCNCC1 XFILUMCRLWWGHF-UHFFFAOYSA-N 0.000 claims description 2
OJAWTIFCYCKDIF-UHFFFAOYSA-N 1-(2-hydroxyethyl)-3-[5-methyl-2-(pyridin-4-ylamino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound N=1C=C2C(C)=CC(NC(=O)NCCO)=NC2=NC=1NC1=CC=NC=C1 OJAWTIFCYCKDIF-UHFFFAOYSA-N 0.000 claims description 2
LWWHQXYBJDKMHB-UHFFFAOYSA-N 1-(4-hydroxycyclohexyl)-3-[2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound C1CC(O)CCC1NC(=O)NC1=CC=C(C=NC(NC=2C=CC(=CC=2)N2CCNCC2)=N2)C2=N1 LWWHQXYBJDKMHB-UHFFFAOYSA-N 0.000 claims description 2
OAZKKGFIMGBLNP-UHFFFAOYSA-N 1-[2-(4-fluoroanilino)pyrido[2,3-d]pyrimidin-7-yl]-3-(2-hydroxyethyl)urea Chemical compound N=1C2=NC(NC(=O)NCCO)=CC=C2C=NC=1NC1=CC=C(F)C=C1 OAZKKGFIMGBLNP-UHFFFAOYSA-N 0.000 claims description 2
XNJIKCCLIKXVKC-UHFFFAOYSA-N 1-[2-(dimethylamino)ethyl]-3-[2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound N=1C2=NC(NC(=O)NCCN(C)C)=CC=C2C=NC=1NC(C=C1)=CC=C1N1CCNCC1 XNJIKCCLIKXVKC-UHFFFAOYSA-N 0.000 claims description 2
HIDCSIGTHYPMDE-UHFFFAOYSA-N 1-[2-[4-(4-acetylpiperazin-1-yl)-3-chloroanilino]pyrido[2,3-d]pyrimidin-7-yl]-3-cyclohexylurea Chemical compound C1CN(C(=O)C)CCN1C(C(=C1)Cl)=CC=C1NC1=NC=C(C=CC(NC(=O)NC2CCCCC2)=N2)C2=N1 HIDCSIGTHYPMDE-UHFFFAOYSA-N 0.000 claims description 2
DWKOQXAXRXLTRO-UHFFFAOYSA-N 1-[2-[4-(4-acetylpiperazin-1-yl)anilino]-5-methylpyrido[2,3-d]pyrimidin-7-yl]-3-(2-hydroxyethyl)urea Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C(C)=CC(NC(=O)NCCO)=N2)C2=N1 DWKOQXAXRXLTRO-UHFFFAOYSA-N 0.000 claims description 2
NSELCHMQELGYCQ-UHFFFAOYSA-N 1-[2-[4-(4-acetylpiperazin-1-yl)anilino]-5-methylpyrido[2,3-d]pyrimidin-7-yl]-3-cyclohexylurea Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C(C)=CC(NC(=O)NC2CCCCC2)=N2)C2=N1 NSELCHMQELGYCQ-UHFFFAOYSA-N 0.000 claims description 2
BPMKMCMJBBHAMO-UHFFFAOYSA-N 1-[2-[4-(4-acetylpiperazin-1-yl)anilino]-5-methylpyrido[2,3-d]pyrimidin-7-yl]-3-ethylurea Chemical compound N=1C2=NC(NC(=O)NCC)=CC(C)=C2C=NC=1NC(C=C1)=CC=C1N1CCN(C(C)=O)CC1 BPMKMCMJBBHAMO-UHFFFAOYSA-N 0.000 claims description 2
QSYGBWVAZZCIDX-UHFFFAOYSA-N 1-[2-[4-(4-acetylpiperazin-1-yl)anilino]pyrido[2,3-d]pyrimidin-7-yl]-3-cyclohexylurea Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C=CC(NC(=O)NC2CCCCC2)=N2)C2=N1 QSYGBWVAZZCIDX-UHFFFAOYSA-N 0.000 claims description 2
YWQNBCXNLXJJFZ-UHFFFAOYSA-N 1-[2-[4-[4-(2-amino-4-methylpentanoyl)piperazin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-yl]-3-cyclohexylurea Chemical compound C1CN(C(=O)C(N)CC(C)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C=CC(NC(=O)NC2CCCCC2)=N2)C2=N1 YWQNBCXNLXJJFZ-UHFFFAOYSA-N 0.000 claims description 2
MQLDVUKGKUIAAL-UHFFFAOYSA-N 1-[5-methyl-2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]-3-propan-2-ylurea Chemical compound N=1C2=NC(NC(=O)NC(C)C)=CC(C)=C2C=NC=1NC(C=C1)=CC=C1N1CCNCC1 MQLDVUKGKUIAAL-UHFFFAOYSA-N 0.000 claims description 2
MGJUUZSZYQUWRL-UHFFFAOYSA-N 1-[6-bromo-2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]-3-cyclohexylurea Chemical compound N1=C2N=C(NC(=O)NC3CCCCC3)C(Br)=CC2=CN=C1NC(C=C1)=CC=C1N1CCNCC1 MGJUUZSZYQUWRL-UHFFFAOYSA-N 0.000 claims description 2
BWORXTLBVMGUGI-UHFFFAOYSA-N 1-[6-bromo-5-methyl-2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]-3-cyclohexylurea Chemical compound N=1C2=NC(NC=3C=CC(=CC=3)N3CCNCC3)=NC=C2C(C)=C(Br)C=1NC(=O)NC1CCCCC1 BWORXTLBVMGUGI-UHFFFAOYSA-N 0.000 claims description 2
ITGHYDKCLQIJEO-UHFFFAOYSA-N 1-[6-chloro-2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]-3-cyclohexylurea Chemical compound N1=C2N=C(NC(=O)NC3CCCCC3)C(Cl)=CC2=CN=C1NC(C=C1)=CC=C1N1CCNCC1 ITGHYDKCLQIJEO-UHFFFAOYSA-N 0.000 claims description 2
UXBCLFZSEPAATK-UHFFFAOYSA-N 1-[6-chloro-5-methyl-2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]-3-cyclohexylurea Chemical compound N=1C2=NC(NC=3C=CC(=CC=3)N3CCNCC3)=NC=C2C(C)=C(Cl)C=1NC(=O)NC1CCCCC1 UXBCLFZSEPAATK-UHFFFAOYSA-N 0.000 claims description 2
FCZSXTNTJURAMC-CALCHBBNSA-N 1-cyclohexyl-3-[2-[4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]anilino]-6-fluoropyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound C1[C@@H](C)N[C@@H](C)CN1C(C=C1)=CC=C1NC1=NC=C(C=C(F)C(NC(=O)NC2CCCCC2)=N2)C2=N1 FCZSXTNTJURAMC-CALCHBBNSA-N 0.000 claims description 2
CKDGTPVNAKRPFN-UHFFFAOYSA-N 1-cyclohexyl-3-[5-methyl-2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]thiourea Chemical compound N=1C2=NC(NC=3C=CC(=CC=3)N3CCNCC3)=NC=C2C(C)=CC=1NC(=S)NC1CCCCC1 CKDGTPVNAKRPFN-UHFFFAOYSA-N 0.000 claims description 2
MPBWULVFTHBBOK-UHFFFAOYSA-N 1-cyclohexyl-3-[5-methyl-2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound N=1C2=NC(NC=3C=CC(=CC=3)N3CCNCC3)=NC=C2C(C)=CC=1NC(=O)NC1CCCCC1 MPBWULVFTHBBOK-UHFFFAOYSA-N 0.000 claims description 2
URTRAPGHHQONHL-UHFFFAOYSA-N 1-cyclohexyl-3-[5-methyl-2-(pyridin-4-ylamino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound N=1C2=NC(NC=3C=CN=CC=3)=NC=C2C(C)=CC=1NC(=O)NC1CCCCC1 URTRAPGHHQONHL-UHFFFAOYSA-N 0.000 claims description 2
ZMWBWZXAOFKNCZ-UHFFFAOYSA-N 1-cyclohexyl-3-[6-fluoro-5-methyl-2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound N=1C2=NC(NC=3C=CC(=CC=3)N3CCNCC3)=NC=C2C(C)=C(F)C=1NC(=O)NC1CCCCC1 ZMWBWZXAOFKNCZ-UHFFFAOYSA-N 0.000 claims description 2
OIFYXWOZMWGIJQ-UHFFFAOYSA-N 1-ethyl-3-[6-fluoro-2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound N=1C=C2C=C(F)C(NC(=O)NCC)=NC2=NC=1NC(C=C1)=CC=C1N1CCNCC1 OIFYXWOZMWGIJQ-UHFFFAOYSA-N 0.000 claims description 2
JMQKXBRWLIMTIU-IYBDPMFKSA-N 1-tert-butyl-3-[2-[4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound C1[C@@H](C)N[C@@H](C)CN1C(C=C1)=CC=C1NC1=NC=C(C=CC(NC(=O)NC(C)(C)C)=N2)C2=N1 JMQKXBRWLIMTIU-IYBDPMFKSA-N 0.000 claims description 2
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 2
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 2
241000124008 Mammalia Species 0.000 claims description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
VVARBBDVASONRD-UHFFFAOYSA-N n-[2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]piperazine-1-carboxamide Chemical compound C1CNCCN1C(=O)NC(N=C1N=2)=CC=C1C=NC=2NC(C=C1)=CC=C1N1CCNCC1 VVARBBDVASONRD-UHFFFAOYSA-N 0.000 claims description 2
125000005143 heteroarylsulfonyl group Chemical group 0.000 claims 4
IZPRSDVSVWVZOM-UHFFFAOYSA-N 1,1-bis(2-hydroxyethyl)-3-[2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound N=1C2=NC(NC(=O)N(CCO)CCO)=CC=C2C=NC=1NC(C=C1)=CC=C1N1CCNCC1 IZPRSDVSVWVZOM-UHFFFAOYSA-N 0.000 claims 1
YACCIEHTQKOSOZ-UHFFFAOYSA-N 1-(3-hydroxypropyl)-3-[2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound N=1C2=NC(NC(=O)NCCCO)=CC=C2C=NC=1NC(C=C1)=CC=C1N1CCNCC1 YACCIEHTQKOSOZ-UHFFFAOYSA-N 0.000 claims 1
OHOPJOZAUWXPDP-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-[2-(4-fluoro-3-methylanilino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound C1=C(F)C(C)=CC(NC=2N=C3N=C(NC(=O)NC=4C=CC(Cl)=CC=4)C=CC3=CN=2)=C1 OHOPJOZAUWXPDP-UHFFFAOYSA-N 0.000 claims 1
YFNIERFVGYMMPV-IBGZPJMESA-N 1-[(2r)-1-hydroxy-3-methylbutan-2-yl]-3-[2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound N=1C2=NC(NC(=O)N[C@@H](CO)C(C)C)=CC=C2C=NC=1NC(C=C1)=CC=C1N1CCNCC1 YFNIERFVGYMMPV-IBGZPJMESA-N 0.000 claims 1
YIGPZBASWQSHAE-IBGZPJMESA-N 1-[(2s)-1-hydroxy-4-methylpentan-2-yl]-3-[2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound N=1C2=NC(NC(=O)N[C@H](CO)CC(C)C)=CC=C2C=NC=1NC(C=C1)=CC=C1N1CCNCC1 YIGPZBASWQSHAE-IBGZPJMESA-N 0.000 claims 1
IWNKWJVEAVWLNF-UHFFFAOYSA-N 1-[2-(4-fluoroanilino)pyrido[2,3-d]pyrimidin-7-yl]-3-(3-morpholin-4-ylpropyl)urea Chemical compound C1=CC(F)=CC=C1NC1=NC=C(C=CC(NC(=O)NCCCN2CCOCC2)=N2)C2=N1 IWNKWJVEAVWLNF-UHFFFAOYSA-N 0.000 claims 1
KEDVKYIYPFUXJF-UHFFFAOYSA-N 1-[2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]-3-propan-2-ylurea Chemical compound N=1C2=NC(NC(=O)NC(C)C)=CC=C2C=NC=1NC(C=C1)=CC=C1N1CCNCC1 KEDVKYIYPFUXJF-UHFFFAOYSA-N 0.000 claims 1
CSHJWZUPBIECMW-UHFFFAOYSA-N 1-[2-(dimethylamino)ethyl]-3-[2-(4-fluoroanilino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound N=1C2=NC(NC(=O)NCCN(C)C)=CC=C2C=NC=1NC1=CC=C(F)C=C1 CSHJWZUPBIECMW-UHFFFAOYSA-N 0.000 claims 1
ZOUYYHCVTKXASL-UHFFFAOYSA-N 1-[2-[4-(4-acetylpiperazin-1-yl)-3-chloroanilino]pyrido[2,3-d]pyrimidin-7-yl]-3-(2-hydroxyethyl)urea Chemical compound C1CN(C(=O)C)CCN1C(C(=C1)Cl)=CC=C1NC1=NC=C(C=CC(NC(=O)NCCO)=N2)C2=N1 ZOUYYHCVTKXASL-UHFFFAOYSA-N 0.000 claims 1
BRJVIFGBXXBAAR-UHFFFAOYSA-N 1-[2-[4-(4-acetylpiperazin-1-yl)anilino]-6-fluoropyrido[2,3-d]pyrimidin-7-yl]-3-ethylurea Chemical compound N=1C=C2C=C(F)C(NC(=O)NCC)=NC2=NC=1NC(C=C1)=CC=C1N1CCN(C(C)=O)CC1 BRJVIFGBXXBAAR-UHFFFAOYSA-N 0.000 claims 1
FZPOQOBRNOTAOD-UHFFFAOYSA-N 1-[2-[4-(4-acetylpiperazin-1-yl)anilino]pyrido[2,3-d]pyrimidin-7-yl]-3-(3-morpholin-4-ylpropyl)urea Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C=CC(NC(=O)NCCCN2CCOCC2)=N2)C2=N1 FZPOQOBRNOTAOD-UHFFFAOYSA-N 0.000 claims 1
SFPLIUUSRNIYCV-CALCHBBNSA-N 1-[2-[4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]anilino]-6-methylpyrido[2,3-d]pyrimidin-7-yl]-3-propan-2-ylurea Chemical compound N=1C=C2C=C(C)C(NC(=O)NC(C)C)=NC2=NC=1NC(C=C1)=CC=C1N1C[C@H](C)N[C@H](C)C1 SFPLIUUSRNIYCV-CALCHBBNSA-N 0.000 claims 1
CCJOQHQBAKQENC-CALCHBBNSA-N 1-[6-bromo-2-[4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-yl]-3-cyclohexylurea Chemical compound C1[C@@H](C)N[C@@H](C)CN1C(C=C1)=CC=C1NC1=NC=C(C=C(Br)C(NC(=O)NC2CCCCC2)=N2)C2=N1 CCJOQHQBAKQENC-CALCHBBNSA-N 0.000 claims 1
BZRTWRVIXYABNX-UHFFFAOYSA-N 1-butyl-3-[2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound N=1C2=NC(NC(=O)NCCCC)=CC=C2C=NC=1NC(C=C1)=CC=C1N1CCNCC1 BZRTWRVIXYABNX-UHFFFAOYSA-N 0.000 claims 1
RSWODMAWDOIYSI-UHFFFAOYSA-N 1-cyclohexyl-3-[2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound C=1C=C2C=NC(NC=3C=CC(=CC=3)N3CCNCC3)=NC2=NC=1NC(=O)NC1CCCCC1 RSWODMAWDOIYSI-UHFFFAOYSA-N 0.000 claims 1
HSXKXMHAELFQJA-UHFFFAOYSA-N 1-cyclohexyl-3-[2-(4-sulfamoylanilino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(C=CC(NC(=O)NC2CCCCC2)=N2)C2=N1 HSXKXMHAELFQJA-UHFFFAOYSA-N 0.000 claims 1
BMTGASBFAFZLBO-UHFFFAOYSA-N 1-cyclohexyl-3-[2-[4-(3,3-dimethylpiperazin-1-yl)anilino]-6-fluoropyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound C1CNC(C)(C)CN1C(C=C1)=CC=C1NC1=NC=C(C=C(F)C(NC(=O)NC2CCCCC2)=N2)C2=N1 BMTGASBFAFZLBO-UHFFFAOYSA-N 0.000 claims 1
APSFLJGQCXHNKS-UHFFFAOYSA-N 1-cyclohexyl-3-[2-[4-(3,3-dimethylpiperazin-1-yl)anilino]pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound C1CNC(C)(C)CN1C(C=C1)=CC=C1NC1=NC=C(C=CC(NC(=O)NC2CCCCC2)=N2)C2=N1 APSFLJGQCXHNKS-UHFFFAOYSA-N 0.000 claims 1
ZTIAGQKFXYSPQF-KDURUIRLSA-N 1-cyclohexyl-3-[2-[4-[(3s,5r)-3,5-dimethylpiperazin-1-yl]anilino]-6-methylpyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound C1[C@@H](C)N[C@@H](C)CN1C(C=C1)=CC=C1NC1=NC=C(C=C(C)C(NC(=O)NC2CCCCC2)=N2)C2=N1 ZTIAGQKFXYSPQF-KDURUIRLSA-N 0.000 claims 1
LEGFPORAUCJVAX-UHFFFAOYSA-N 1-cyclohexyl-3-[6-fluoro-2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound N1=C2N=C(NC(=O)NC3CCCCC3)C(F)=CC2=CN=C1NC(C=C1)=CC=C1N1CCNCC1 LEGFPORAUCJVAX-UHFFFAOYSA-N 0.000 claims 1
KECDAYXAFLSFRM-UHFFFAOYSA-N 1-cyclopentyl-3-[2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound C=1C=C2C=NC(NC=3C=CC(=CC=3)N3CCNCC3)=NC2=NC=1NC(=O)NC1CCCC1 KECDAYXAFLSFRM-UHFFFAOYSA-N 0.000 claims 1
CZKTXARZWICZDX-IYBDPMFKSA-N 1-cyclopropyl-3-[2-[4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]anilino]-6-methylpyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound C1[C@@H](C)N[C@@H](C)CN1C(C=C1)=CC=C1NC1=NC=C(C=C(C)C(NC(=O)NC2CC2)=N2)C2=N1 CZKTXARZWICZDX-IYBDPMFKSA-N 0.000 claims 1
GYYKVWXKLILFFC-UHFFFAOYSA-N 1-ethyl-3-[2-(pyridin-4-ylamino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound N=1C2=NC(NC(=O)NCC)=CC=C2C=NC=1NC1=CC=NC=C1 GYYKVWXKLILFFC-UHFFFAOYSA-N 0.000 claims 1
TUWWKUILUSIXFY-UHFFFAOYSA-N 1-methyl-3-[5-methyl-2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound N=1C2=NC(NC(=O)NC)=CC(C)=C2C=NC=1NC(C=C1)=CC=C1N1CCNCC1 TUWWKUILUSIXFY-UHFFFAOYSA-N 0.000 claims 1
SXXFFZGOAOAHCL-UHFFFAOYSA-N 1-tert-butyl-3-[2-(3-chloro-4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound N=1C2=NC(NC(=O)NC(C)(C)C)=CC=C2C=NC=1NC(C=C1Cl)=CC=C1N1CCNCC1 SXXFFZGOAOAHCL-UHFFFAOYSA-N 0.000 claims 1
IWQRQXJFCBIGMI-CALCHBBNSA-N 1-tert-butyl-3-[2-[4-[(3s,5r)-3,5-dimethylpiperazin-1-yl]anilino]-6-methylpyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound C1[C@@H](C)N[C@@H](C)CN1C(C=C1)=CC=C1NC1=NC=C(C=C(C)C(NC(=O)NC(C)(C)C)=N2)C2=N1 IWQRQXJFCBIGMI-CALCHBBNSA-N 0.000 claims 1
PBUDIXSYLRMHOQ-UHFFFAOYSA-N 1-tert-butyl-3-[6-fluoro-2-(pyridin-4-ylamino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound N=1C=C2C=C(F)C(NC(=O)NC(C)(C)C)=NC2=NC=1NC1=CC=NC=C1 PBUDIXSYLRMHOQ-UHFFFAOYSA-N 0.000 claims 1
JCVWHDFOLJVVDR-KDURUIRLSA-N 3-cyclohexyl-1-[2-[4-[(3s,5r)-3,5-dimethylpiperazin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-yl]-1-methylurea Chemical compound C1[C@@H](C)N[C@@H](C)CN1C(C=C1)=CC=C1NC1=NC=C(C=CC(=N2)N(C)C(=O)NC3CCCCC3)C2=N1 JCVWHDFOLJVVDR-KDURUIRLSA-N 0.000 claims 1
PJYOLZRAIFCFFW-UHFFFAOYSA-N 3-cyclohexyl-1-ethyl-1-[2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound C=1C=C2C=NC(NC=3C=CC(=CC=3)N3CCNCC3)=NC2=NC=1N(CC)C(=O)NC1CCCCC1 PJYOLZRAIFCFFW-UHFFFAOYSA-N 0.000 claims 1
FTZPYSIBTYNADH-UHFFFAOYSA-N 4-methyl-n-[2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]piperazine-1-carboxamide Chemical compound C1CN(C)CCN1C(=O)NC1=CC=C(C=NC(NC=2C=CC(=CC=2)N2CCNCC2)=N2)C2=N1 FTZPYSIBTYNADH-UHFFFAOYSA-N 0.000 claims 1
206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
241000271569 Rhea Species 0.000 claims 1
206010057469 Vascular stenosis Diseases 0.000 claims 1
125000004429 atom Chemical group 0.000 claims 1
230000003328 fibroblastic effect Effects 0.000 claims 1
125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
230000003902 lesion Effects 0.000 claims 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
SVNXEKWFYUHVHU-UHFFFAOYSA-N n-[2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]morpholine-4-carboxamide Chemical compound C1COCCN1C(=O)NC(N=C1N=2)=CC=C1C=NC=2NC(C=C1)=CC=C1N1CCNCC1 SVNXEKWFYUHVHU-UHFFFAOYSA-N 0.000 claims 1
201000002528 pancreatic cancer Diseases 0.000 claims 1
208000008443 pancreatic carcinoma Diseases 0.000 claims 1
NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 claims 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
238000011282 treatment Methods 0.000 abstract description 16
239000003112 inhibitor Substances 0.000 abstract description 8
230000003389 potentiating effect Effects 0.000 abstract description 7
108091000080 Phosphotransferase Proteins 0.000 abstract description 6
102000020233 phosphotransferase Human genes 0.000 abstract description 6
125000005843 halogen group Chemical group 0.000 abstract 2
101150020251 NR13 gene Proteins 0.000 abstract 1
239000000047 product Substances 0.000 description 145
239000007787 solid Substances 0.000 description 83
239000000243 solution Substances 0.000 description 52
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 40
239000012265 solid product Substances 0.000 description 38
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
239000000203 mixture Substances 0.000 description 31
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
239000000725 suspension Substances 0.000 description 28
238000003786 synthesis reaction Methods 0.000 description 25
230000015572 biosynthetic process Effects 0.000 description 24
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 23
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
238000006243 chemical reaction Methods 0.000 description 20
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
239000004480 active ingredient Substances 0.000 description 17
239000002244 precipitate Substances 0.000 description 17
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
239000011541 reaction mixture Substances 0.000 description 15
238000002360 preparation method Methods 0.000 description 13
GBTYIAXFRCTFAA-UHFFFAOYSA-N 2-methylsulfinylpyrido[2,3-d]pyrimidin-7-amine Chemical compound C1=CC(N)=NC2=NC(S(=O)C)=NC=C21 GBTYIAXFRCTFAA-UHFFFAOYSA-N 0.000 description 12
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 12
239000002775 capsule Substances 0.000 description 12
230000005764 inhibitory process Effects 0.000 description 11
239000003826 tablet Substances 0.000 description 11
210000004027 cell Anatomy 0.000 description 10
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 10
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 9
239000002253 acid Substances 0.000 description 9
230000000694 effects Effects 0.000 description 9
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
229910052943 magnesium sulfate Inorganic materials 0.000 description 8
235000019341 magnesium sulphate Nutrition 0.000 description 8
229920006395 saturated elastomer Polymers 0.000 description 8
239000007858 starting material Substances 0.000 description 8
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 7
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
229920002472 Starch Polymers 0.000 description 7
239000000872 buffer Substances 0.000 description 7
235000013877 carbamide Nutrition 0.000 description 7
238000003818 flash chromatography Methods 0.000 description 7
229910000104 sodium hydride Inorganic materials 0.000 description 7
239000008107 starch Substances 0.000 description 7
235000019698 starch Nutrition 0.000 description 7
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
GVXVSVNJQPKFPZ-UHFFFAOYSA-N 1-(4-amino-2-methylsulfanylpyrimidin-5-yl)ethanone Chemical compound CSC1=NC=C(C(C)=O)C(N)=N1 GVXVSVNJQPKFPZ-UHFFFAOYSA-N 0.000 description 6
FGONQMFYFJRAIG-UHFFFAOYSA-N 4-amino-2-methylsulfanylpyrimidine-5-carbaldehyde Chemical compound CSC1=NC=C(C=O)C(N)=N1 FGONQMFYFJRAIG-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
102000001332 SRC Human genes 0.000 description 6
108060006706 SRC Proteins 0.000 description 6
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
230000022131 cell cycle Effects 0.000 description 6
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 6
239000000843 powder Substances 0.000 description 6
RXFHRKPNLPBDGE-UHFFFAOYSA-N tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(N)C=C1 RXFHRKPNLPBDGE-UHFFFAOYSA-N 0.000 description 6
MGYCIJUTYLUYJM-UHFFFAOYSA-N tert-butyl 4-(4-nitrophenyl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C([N+]([O-])=O)C=C1 MGYCIJUTYLUYJM-UHFFFAOYSA-N 0.000 description 6
QYODGURZVDETMS-UHFFFAOYSA-N tert-butyl 4-[4-[[7-(cyclohexylcarbamoylamino)pyrido[2,3-d]pyrimidin-2-yl]amino]phenyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C=CC(NC(=O)NC2CCCCC2)=N2)C2=N1 QYODGURZVDETMS-UHFFFAOYSA-N 0.000 description 6
OXXHQZJBSKTBQV-UHFFFAOYSA-N 2-methylsulfanylpyrido[2,3-d]pyrimidin-7-amine Chemical compound C1=CC(N)=NC2=NC(SC)=NC=C21 OXXHQZJBSKTBQV-UHFFFAOYSA-N 0.000 description 5
102000003903 Cyclin-dependent kinases Human genes 0.000 description 5
108090000266 Cyclin-dependent kinases Proteins 0.000 description 5
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
241000238631 Hexapoda Species 0.000 description 5
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
239000011324 bead Substances 0.000 description 5
125000004432 carbon atom Chemical group C* 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
239000000460 chlorine Substances 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
239000000706 filtrate Substances 0.000 description 5
238000009472 formulation Methods 0.000 description 5
238000011534 incubation Methods 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
239000011734 sodium Substances 0.000 description 5
239000012312 sodium hydride Substances 0.000 description 5
239000012453 solvate Substances 0.000 description 5
125000001424 substituent group Chemical group 0.000 description 5
239000000758 substrate Substances 0.000 description 5
QUKABSSPBMVPRN-UHFFFAOYSA-N tert-butyl 4-(4-aminophenyl)-2,2-dimethylpiperazine-1-carboxylate Chemical compound C1C(C)(C)N(C(=O)OC(C)(C)C)CCN1C1=CC=C(N)C=C1 QUKABSSPBMVPRN-UHFFFAOYSA-N 0.000 description 5
RAQHINAQAPWZKV-UHFFFAOYSA-N 1-(4-amino-2-methylsulfinylpyrimidin-5-yl)ethanone Chemical compound CC(=O)C1=CN=C(S(C)=O)N=C1N RAQHINAQAPWZKV-UHFFFAOYSA-N 0.000 description 4
VGFQMCUDJBVYIU-UHFFFAOYSA-N 1-[2-[4-(4-acetylpiperazin-1-yl)-3-chloroanilino]pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea Chemical compound C1CN(C(=O)C)CCN1C(C(=C1)Cl)=CC=C1NC1=NC=C(C=CC(NC(=O)NC(C)(C)C)=N2)C2=N1 VGFQMCUDJBVYIU-UHFFFAOYSA-N 0.000 description 4
HZFMETOCPOTWHF-UHFFFAOYSA-N 4-[4-[(7-amino-5-methylpyrido[2,3-d]pyrimidin-2-yl)amino]phenyl]piperazine-1-carboxylic acid Chemical compound N=1C=C2C(C)=CC(N)=NC2=NC=1NC(C=C1)=CC=C1N1CCN(C(O)=O)CC1 HZFMETOCPOTWHF-UHFFFAOYSA-N 0.000 description 4
BTVINKYGRDLXBP-UHFFFAOYSA-N 5-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-amine Chemical compound CC1=CC(N)=NC2=NC(SC)=NC=C21 BTVINKYGRDLXBP-UHFFFAOYSA-N 0.000 description 4
HEXUGCQBLSDFMP-UHFFFAOYSA-N 6-fluoro-2-methylsulfanyl-8h-pyrido[2,3-d]pyrimidin-7-one Chemical compound C1=C(F)C(=O)NC2=NC(SC)=NC=C21 HEXUGCQBLSDFMP-UHFFFAOYSA-N 0.000 description 4
XTSLSQONBOVLCD-UHFFFAOYSA-N 6-fluoro-2-methylsulfinylpyrido[2,3-d]pyrimidin-7-amine Chemical compound C1=C(F)C(N)=NC2=NC(S(=O)C)=NC=C21 XTSLSQONBOVLCD-UHFFFAOYSA-N 0.000 description 4
KNLKKWMQDADZHW-UHFFFAOYSA-N 7-chloro-6-fluoro-2-methylsulfanylpyrido[2,3-d]pyrimidine Chemical compound C1=C(F)C(Cl)=NC2=NC(SC)=NC=C21 KNLKKWMQDADZHW-UHFFFAOYSA-N 0.000 description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical class N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
201000009030 Carcinoma Diseases 0.000 description 4
101150053721 Cdk5 gene Proteins 0.000 description 4
101150093908 PDGFRB gene Proteins 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
102000001253 Protein Kinase Human genes 0.000 description 4
239000007983 Tris buffer Substances 0.000 description 4
102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 4
NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate group Chemical group C(C=C)(=O)[O-] NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
235000019270 ammonium chloride Nutrition 0.000 description 4
239000002585 base Substances 0.000 description 4
150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
238000000354 decomposition reaction Methods 0.000 description 4
239000007788 liquid Substances 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
239000000463 material Substances 0.000 description 4
239000012044 organic layer Substances 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
108060006633 protein kinase Proteins 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical compound C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
239000000829 suppository Substances 0.000 description 4
239000000454 talc Substances 0.000 description 4
229910052623 talc Inorganic materials 0.000 description 4
GSALRQQUCCLTEJ-BETUJISGSA-N tert-butyl (2s,6r)-4-(4-aminophenyl)-2,6-dimethylpiperazine-1-carboxylate Chemical compound C1[C@@H](C)N(C(=O)OC(C)(C)C)[C@@H](C)CN1C1=CC=C(N)C=C1 GSALRQQUCCLTEJ-BETUJISGSA-N 0.000 description 4
WOUUQSHQQVGNPK-UHFFFAOYSA-N tert-butyl 4-[4-[[7-(cyclopentylcarbamoylamino)-5-methylpyrido[2,3-d]pyrimidin-2-yl]amino]phenyl]piperazine-1-carboxylate Chemical compound N=1C2=NC(NC=3C=CC(=CC=3)N3CCN(CC3)C(=O)OC(C)(C)C)=NC=C2C(C)=CC=1NC(=O)NC1CCCC1 WOUUQSHQQVGNPK-UHFFFAOYSA-N 0.000 description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
VWOJSRICSKDKAW-UHFFFAOYSA-N 1-(4-nitrophenyl)piperazine Chemical compound C1=CC([N+](=O)[O-])=CC=C1N1CCNCC1 VWOJSRICSKDKAW-UHFFFAOYSA-N 0.000 description 3
VRPPJKBHZOYBJJ-UHFFFAOYSA-N 2-phenyl-1H-pyrido[2,3-d]pyrimidine-2,7-diamine Chemical compound C1(=CC=CC=C1)C1(N=CC2=C(N1)N=C(C=C2)N)N VRPPJKBHZOYBJJ-UHFFFAOYSA-N 0.000 description 3
YWBCNTSYSJKVFM-UHFFFAOYSA-N 4-[4-[[7-(cyclohexylcarbamoylamino)-5-methylpyrido[2,3-d]pyrimidin-2-yl]amino]phenyl]piperazine-1-carboxylic acid Chemical compound N=1C2=NC(NC=3C=CC(=CC=3)N3CCN(CC3)C(O)=O)=NC=C2C(C)=CC=1NC(=O)NC1CCCCC1 YWBCNTSYSJKVFM-UHFFFAOYSA-N 0.000 description 3
XJTBMLQVSGDVOT-UHFFFAOYSA-N 5-methyl-2-methylsulfinylpyrido[2,3-d]pyrimidin-7-amine Chemical compound CS(=O)C1=NC=C2C(C)=CC(N)=NC2=N1 XJTBMLQVSGDVOT-UHFFFAOYSA-N 0.000 description 3
BSKBDNXMRMMXLQ-UHFFFAOYSA-N 6-fluoro-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-amine Chemical compound C1=C(F)C(N)=NC2=NC(SC)=NC=C21 BSKBDNXMRMMXLQ-UHFFFAOYSA-N 0.000 description 3
UNAVSLNMFZKAMD-UHFFFAOYSA-N 7-chloro-2-methylsulfanylpyrido[2,3-d]pyrimidine Chemical compound C1=CC(Cl)=NC2=NC(SC)=NC=C21 UNAVSLNMFZKAMD-UHFFFAOYSA-N 0.000 description 3
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
108091007914 CDKs Proteins 0.000 description 3
102000016736 Cyclin Human genes 0.000 description 3
108050006400 Cyclin Proteins 0.000 description 3
206010012689 Diabetic retinopathy Diseases 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 3
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
241000700605 Viruses Species 0.000 description 3
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
239000000908 ammonium hydroxide Substances 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000013592 cell lysate Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
229940125797 compound 12 Drugs 0.000 description 3
KQWGXHWJMSMDJJ-UHFFFAOYSA-N cyclohexyl isocyanate Chemical compound O=C=NC1CCCCC1 KQWGXHWJMSMDJJ-UHFFFAOYSA-N 0.000 description 3
NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
239000008187 granular material Substances 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 3
230000005012 migration Effects 0.000 description 3
238000013508 migration Methods 0.000 description 3
239000006186 oral dosage form Substances 0.000 description 3
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 3
230000026731 phosphorylation Effects 0.000 description 3
238000006366 phosphorylation reaction Methods 0.000 description 3
RFIOZSIHFNEKFF-UHFFFAOYSA-N piperazine-1-carboxylic acid Chemical compound OC(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-N 0.000 description 3
235000017557 sodium bicarbonate Nutrition 0.000 description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 3
229940048086 sodium pyrophosphate Drugs 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
125000003107 substituted aryl group Chemical group 0.000 description 3
239000011593 sulfur Chemical group 0.000 description 3
SFCPIVBCNGQUJZ-OYRHEFFESA-N tert-butyl (2r,6s)-4-[4-[[7-(cyclohexylcarbamoylamino)pyrido[2,3-d]pyrimidin-2-yl]amino]phenyl]-2,6-dimethylpiperazine-1-carboxylate Chemical compound C1[C@@H](C)N(C(=O)OC(C)(C)C)[C@@H](C)CN1C(C=C1)=CC=C1NC1=NC=C(C=CC(NC(=O)NC2CCCCC2)=N2)C2=N1 SFCPIVBCNGQUJZ-OYRHEFFESA-N 0.000 description 3
QRWVTEIEDYKPMU-UHFFFAOYSA-N tert-butyl 4-[4-[[7-(cyclopentylcarbamoylamino)pyrido[2,3-d]pyrimidin-2-yl]amino]phenyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C=CC(NC(=O)NC2CCCC2)=N2)C2=N1 QRWVTEIEDYKPMU-UHFFFAOYSA-N 0.000 description 3
CNYRDNMCDSPEBQ-UHFFFAOYSA-N tert-butyl 4-[4-[[7-(tert-butylcarbamoylamino)-5-methylpyrido[2,3-d]pyrimidin-2-yl]amino]phenyl]piperazine-1-carboxylate Chemical compound N=1C=C2C(C)=CC(NC(=O)NC(C)(C)C)=NC2=NC=1NC(C=C1)=CC=C1N1CCN(C(=O)OC(C)(C)C)CC1 CNYRDNMCDSPEBQ-UHFFFAOYSA-N 0.000 description 3
238000012360 testing method Methods 0.000 description 3
235000019818 tetrasodium diphosphate Nutrition 0.000 description 3
239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 3
239000001993 wax Substances 0.000 description 3
VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 2
VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 2
UBLZWKCJZSDBGQ-AOOOYVTPSA-N (3r,5s)-3,5-dimethyl-1-(4-nitrophenyl)piperazine Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=CC=C([N+]([O-])=O)C=C1 UBLZWKCJZSDBGQ-AOOOYVTPSA-N 0.000 description 2
125000000008 (C1-C10) alkyl group Chemical group 0.000 description 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
PHSHJESWCRAZQE-UHFFFAOYSA-N 1-(4-amino-2-methylsulfanylpyrimidin-5-yl)ethanol Chemical compound CSC1=NC=C(C(C)O)C(N)=N1 PHSHJESWCRAZQE-UHFFFAOYSA-N 0.000 description 2
ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 2
VZAWCLCJGSBATP-UHFFFAOYSA-N 1-cycloundecyl-1,2-diazacycloundecane Chemical compound C1CCCCCCCCCC1N1NCCCCCCCCC1 VZAWCLCJGSBATP-UHFFFAOYSA-N 0.000 description 2
RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 2
KWMBADTWRIGGGG-UHFFFAOYSA-N 2-diethoxyphosphorylacetonitrile Chemical compound CCOP(=O)(CC#N)OCC KWMBADTWRIGGGG-UHFFFAOYSA-N 0.000 description 2
GSLTVFIVJMCNBH-UHFFFAOYSA-N 2-isocyanatopropane Chemical compound CC(C)N=C=O GSLTVFIVJMCNBH-UHFFFAOYSA-N 0.000 description 2
WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 2
QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 2
UIKUBYKUYUSRSM-UHFFFAOYSA-N 3-morpholinopropylamine Chemical compound NCCCN1CCOCC1 UIKUBYKUYUSRSM-UHFFFAOYSA-N 0.000 description 2
KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 2
CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical class CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
206010005003 Bladder cancer Diseases 0.000 description 2
241000514744 Cyclina Species 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
108010033040 Histones Proteins 0.000 description 2
102000006947 Histones Human genes 0.000 description 2
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 2
JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
201000000582 Retinoblastoma Diseases 0.000 description 2
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
102100031167 Tyrosine-protein kinase CSK Human genes 0.000 description 2
101710086605 Tyrosine-protein kinase CSK Proteins 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
FPVUCBMBMUHRDX-XMMPIXPASA-N [4-hydroxy-3-(3-methylbut-2-enyl)phenyl]methyl (2r)-4-hydroxy-3-(4-hydroxyphenyl)-2-methyl-5-oxofuran-2-carboxylate Chemical compound C1=C(O)C(CC=C(C)C)=CC(COC(=O)[C@@]2(C)C(=C(O)C(=O)O2)C=2C=CC(O)=CC=2)=C1 FPVUCBMBMUHRDX-XMMPIXPASA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
239000012346 acetyl chloride Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
230000033115 angiogenesis Effects 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
201000001531 bladder carcinoma Diseases 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
239000012267 brine Substances 0.000 description 2
125000001589 carboacyl group Chemical group 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
239000003086 colorant Substances 0.000 description 2
229940125904 compound 1 Drugs 0.000 description 2
239000013068 control sample Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000001952 enzyme assay Methods 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000012634 fragment Substances 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000003993 interaction Effects 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
239000012948 isocyanate Substances 0.000 description 2
150000002513 isocyanates Chemical class 0.000 description 2
238000002955 isolation Methods 0.000 description 2
238000000021 kinase assay Methods 0.000 description 2
239000004816 latex Substances 0.000 description 2
229920000126 latex Polymers 0.000 description 2
239000008297 liquid dosage form Substances 0.000 description 2
239000006166 lysate Substances 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
238000002844 melting Methods 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
102000037979 non-receptor tyrosine kinases Human genes 0.000 description 2
108091008046 non-receptor tyrosine kinases Proteins 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
239000006187 pill Substances 0.000 description 2
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
125000004193 piperazinyl group Chemical group 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
230000008569 process Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
UVBZDRKTCAJYLN-UHFFFAOYSA-N pyrido[3,2-d]pyrimidin-7-amine Chemical compound C1=NC=NC2=CC(N)=CN=C21 UVBZDRKTCAJYLN-UHFFFAOYSA-N 0.000 description 2
150000003230 pyrimidines Chemical class 0.000 description 2
125000000719 pyrrolidinyl group Chemical group 0.000 description 2
108091008598 receptor tyrosine kinases Proteins 0.000 description 2
102000027426 receptor tyrosine kinases Human genes 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
239000000523 sample Substances 0.000 description 2
238000000926 separation method Methods 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
239000002002 slurry Substances 0.000 description 2
239000004299 sodium benzoate Substances 0.000 description 2
235000010234 sodium benzoate Nutrition 0.000 description 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
239000007909 solid dosage form Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000010189 synthetic method Methods 0.000 description 2
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
OSBIEGRZGZRSBF-UHFFFAOYSA-N tert-butyl 4-[4-[(5-acetyl-4-aminopyrimidin-2-yl)amino]phenyl]piperazine-1-carboxylate Chemical compound N1=C(N)C(C(=O)C)=CN=C1NC1=CC=C(N2CCN(CC2)C(=O)OC(C)(C)C)C=C1 OSBIEGRZGZRSBF-UHFFFAOYSA-N 0.000 description 2
PWUUIKXPHXIFIT-UHFFFAOYSA-N tert-butyl 4-[4-[(7-amino-5-methylpyrido[2,3-d]pyrimidin-2-yl)amino]phenyl]piperazine-1-carboxylate Chemical compound N=1C=C2C(C)=CC(N)=NC2=NC=1NC(C=C1)=CC=C1N1CCN(C(=O)OC(C)(C)C)CC1 PWUUIKXPHXIFIT-UHFFFAOYSA-N 0.000 description 2
CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
241000701447 unidentified baculovirus Species 0.000 description 2
208000010570 urinary bladder carcinoma Diseases 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
VPSSPAXIFBTOHY-LURJTMIESA-N (2s)-2-amino-4-methylpentan-1-ol Chemical compound CC(C)C[C@H](N)CO VPSSPAXIFBTOHY-LURJTMIESA-N 0.000 description 1
STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
IFNWESYYDINUHV-OLQVQODUSA-N (2s,6r)-2,6-dimethylpiperazine Chemical compound C[C@H]1CNC[C@@H](C)N1 IFNWESYYDINUHV-OLQVQODUSA-N 0.000 description 1
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
FNHHVPPSBFQMEL-KQHDFZBMSA-N (3S)-5-N-[(1S,5R)-3-hydroxy-6-bicyclo[3.1.0]hexanyl]-7-N,3-dimethyl-3-phenyl-2H-1-benzofuran-5,7-dicarboxamide Chemical compound CNC(=O)c1cc(cc2c1OC[C@@]2(C)c1ccccc1)C(=O)NC1[C@H]2CC(O)C[C@@H]12 FNHHVPPSBFQMEL-KQHDFZBMSA-N 0.000 description 1
IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
XLVOWGDFXAVSFE-UHFFFAOYSA-N (4-amino-2-methylsulfanylpyrimidin-5-yl)methanol Chemical compound CSC1=NC=C(CO)C(N)=N1 XLVOWGDFXAVSFE-UHFFFAOYSA-N 0.000 description 1
YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 1
125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 1
125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
125000006824 (C1-C6) dialkyl amine group Chemical group 0.000 description 1
ZLHKUOXVUSHCLN-UHFFFAOYSA-N (furan-2-ylmethylideneamino)thiourea Chemical compound NC(=S)NN=CC1=CC=CO1 ZLHKUOXVUSHCLN-UHFFFAOYSA-N 0.000 description 1
MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
DJMOXMNDXFFONV-UHFFFAOYSA-N 1,3-dimethyl-7-[2-(n-methylanilino)ethyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCN(C)C1=CC=CC=C1 DJMOXMNDXFFONV-UHFFFAOYSA-N 0.000 description 1
JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
SOMPXJVENKFJQG-UHFFFAOYSA-N 1-(2-aminoethyl)-3-[2-(4-fluoroanilino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound N=1C2=NC(NC(=O)NCCN)=CC=C2C=NC=1NC1=CC=C(F)C=C1 SOMPXJVENKFJQG-UHFFFAOYSA-N 0.000 description 1
MRBJJIIFXAMERI-UHFFFAOYSA-N 1-(2-anilinopyrido[2,3-d]pyrimidin-7-yl)-3-tert-butylurea Chemical compound N=1C2=NC(NC(=O)NC(C)(C)C)=CC=C2C=NC=1NC1=CC=CC=C1 MRBJJIIFXAMERI-UHFFFAOYSA-N 0.000 description 1
QPUDAOMKURLGLK-UHFFFAOYSA-N 1-(4-aminocyclohexyl)-3-[2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound C1CC(N)CCC1NC(=O)NC1=CC=C(C=NC(NC=2C=CC(=CC=2)N2CCNCC2)=N2)C2=N1 QPUDAOMKURLGLK-UHFFFAOYSA-N 0.000 description 1
KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
SNAZOIMRWKVMNQ-UHFFFAOYSA-N 1-[2-(3-chloro-4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]-3-cyclohexylurea Chemical compound C=1C=C(N2CCNCC2)C(Cl)=CC=1NC(N=C1N=2)=NC=C1C=CC=2NC(=O)NC1CCCCC1 SNAZOIMRWKVMNQ-UHFFFAOYSA-N 0.000 description 1
ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
ZDQUGBAOJVAHFP-UHFFFAOYSA-N 1-[2-[4-(4-acetylpiperazin-1-yl)anilino]-5-methylpyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C(C)=CC(NC(=O)NC(C)(C)C)=N2)C2=N1 ZDQUGBAOJVAHFP-UHFFFAOYSA-N 0.000 description 1
UUJKLLDOWWAPFC-UHFFFAOYSA-N 1-[2-[4-(4-acetylpiperazin-1-yl)anilino]-6-fluoropyrido[2,3-d]pyrimidin-7-yl]-3-cyclohexylurea Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C=C(F)C(NC(=O)NC2CCCCC2)=N2)C2=N1 UUJKLLDOWWAPFC-UHFFFAOYSA-N 0.000 description 1
VWUJZWLAORFRFO-UHFFFAOYSA-N 1-[2-[4-(4-acetylpiperazin-1-yl)anilino]-6-fluoropyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C=C(F)C(NC(=O)NC(C)(C)C)=N2)C2=N1 VWUJZWLAORFRFO-UHFFFAOYSA-N 0.000 description 1
GFUIAAHVXBLQBC-UHFFFAOYSA-N 1-[2-[4-[4-(2-amino-3-methylbutanoyl)piperazin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-yl]-3-cyclohexylurea Chemical compound C1CN(C(=O)C(N)C(C)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C=CC(NC(=O)NC2CCCCC2)=N2)C2=N1 GFUIAAHVXBLQBC-UHFFFAOYSA-N 0.000 description 1
AFVUJJNEILZYJQ-UHFFFAOYSA-N 1-[4-(4-aminophenyl)-1-piperazinyl]ethanone Chemical compound C1CN(C(=O)C)CCN1C1=CC=C(N)C=C1 AFVUJJNEILZYJQ-UHFFFAOYSA-N 0.000 description 1
QUZMCJMGHMRZHA-UHFFFAOYSA-N 1-[4-(4-nitrophenyl)piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C1=CC=C([N+]([O-])=O)C=C1 QUZMCJMGHMRZHA-UHFFFAOYSA-N 0.000 description 1
GUIPAUCBZRMQRW-UHFFFAOYSA-N 1-[6-bromo-2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]-3-methylurea Chemical compound N=1C=C2C=C(Br)C(NC(=O)NC)=NC2=NC=1NC(C=C1)=CC=C1N1CCNCC1 GUIPAUCBZRMQRW-UHFFFAOYSA-N 0.000 description 1
PHULBAMDTWXUMM-GASCZTMLSA-N 1-[6-bromo-2-[4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea Chemical compound C1[C@@H](C)N[C@@H](C)CN1C(C=C1)=CC=C1NC1=NC=C(C=C(Br)C(NC(=O)NC(C)(C)C)=N2)C2=N1 PHULBAMDTWXUMM-GASCZTMLSA-N 0.000 description 1
PKJBWOWQJHHAHG-UHFFFAOYSA-N 1-bromo-4-phenylbenzene Chemical group C1=CC(Br)=CC=C1C1=CC=CC=C1 PKJBWOWQJHHAHG-UHFFFAOYSA-N 0.000 description 1
ADAKRBAJFHTIEW-UHFFFAOYSA-N 1-chloro-4-isocyanatobenzene Chemical compound ClC1=CC=C(N=C=O)C=C1 ADAKRBAJFHTIEW-UHFFFAOYSA-N 0.000 description 1
LNDIIIZPJOCMAU-UHFFFAOYSA-N 1-cyclohexyl-3-[6-fluoro-2-(pyridin-4-ylamino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound N1=C2N=C(NC(=O)NC3CCCCC3)C(F)=CC2=CN=C1NC1=CC=NC=C1 LNDIIIZPJOCMAU-UHFFFAOYSA-N 0.000 description 1
BAZVIVARXKYKOK-UHFFFAOYSA-N 1-cyclohexyl-3-[6-methyl-2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound N1=C2N=C(NC(=O)NC3CCCCC3)C(C)=CC2=CN=C1NC(C=C1)=CC=C1N1CCNCC1 BAZVIVARXKYKOK-UHFFFAOYSA-N 0.000 description 1
VNSZTBUYZONSHT-UHFFFAOYSA-N 1-cyclopentyl-3-[5-methyl-2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound N=1C2=NC(NC=3C=CC(=CC=3)N3CCNCC3)=NC=C2C(C)=CC=1NC(=O)NC1CCCC1 VNSZTBUYZONSHT-UHFFFAOYSA-N 0.000 description 1
LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical class CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
PULCUZSSHSLGTG-UHFFFAOYSA-N 1-ethyl-3-[6-fluoro-2-(pyridin-4-ylamino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound N=1C=C2C=C(F)C(NC(=O)NCC)=NC2=NC=1NC1=CC=NC=C1 PULCUZSSHSLGTG-UHFFFAOYSA-N 0.000 description 1
WFQDTOYDVUWQMS-UHFFFAOYSA-N 1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1 WFQDTOYDVUWQMS-UHFFFAOYSA-N 0.000 description 1
125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
125000006052 1-methyl-3-pentenyl group Chemical group 0.000 description 1
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
FZYSIWYOHGFZSV-GASCZTMLSA-N 1-tert-butyl-3-[2-[4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]anilino]-6-fluoropyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound C1[C@@H](C)N[C@@H](C)CN1C(C=C1)=CC=C1NC1=NC=C(C=C(F)C(NC(=O)NC(C)(C)C)=N2)C2=N1 FZYSIWYOHGFZSV-GASCZTMLSA-N 0.000 description 1
BDWLNZXAMQPJNX-CALCHBBNSA-N 1-tert-butyl-3-[2-[4-[(3s,5r)-3,5-dimethylpiperazin-1-yl]anilino]-6-ethylpyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound N1=C2N=C(NC(=O)NC(C)(C)C)C(CC)=CC2=CN=C1NC(C=C1)=CC=C1N1C[C@H](C)N[C@H](C)C1 BDWLNZXAMQPJNX-CALCHBBNSA-N 0.000 description 1
DMQGWXYTVMVWCU-UHFFFAOYSA-N 1-tert-butyl-3-[5-methyl-2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound N=1C=C2C(C)=CC(NC(=O)NC(C)(C)C)=NC2=NC=1NC(C=C1)=CC=C1N1CCNCC1 DMQGWXYTVMVWCU-UHFFFAOYSA-N 0.000 description 1
FTPGODXQOCTHDX-UHFFFAOYSA-N 1-tert-butyl-3-[6-fluoro-2-(4-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-yl]urea Chemical compound N=1C=C2C=C(F)C(NC(=O)NC(C)(C)C)=NC2=NC=1NC(C=C1)=CC=C1N1CCNCC1 FTPGODXQOCTHDX-UHFFFAOYSA-N 0.000 description 1
125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
PIPWSBOFSUJCCO-UHFFFAOYSA-N 2,2-dimethylpiperazine Chemical group CC1(C)CNCCN1 PIPWSBOFSUJCCO-UHFFFAOYSA-N 0.000 description 1
CQZCBLLPJONWCZ-UHFFFAOYSA-N 2,2-dimethylpiperazine-1-carboxylic acid Chemical compound CC1(C)CNCCN1C(O)=O CQZCBLLPJONWCZ-UHFFFAOYSA-N 0.000 description 1
WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 1
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
ZTGBKXVQAMZVAI-UHFFFAOYSA-N 2-diethoxyphosphorylbutanenitrile Chemical compound CCOP(=O)(OCC)C(CC)C#N ZTGBKXVQAMZVAI-UHFFFAOYSA-N 0.000 description 1
UMLWEPGSWQNXQX-UHFFFAOYSA-N 2-diethoxyphosphorylpropanenitrile Chemical compound CCOP(=O)(OCC)C(C)C#N UMLWEPGSWQNXQX-UHFFFAOYSA-N 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
DPAYLXMDZVRDOT-UHFFFAOYSA-N 2-methyl-6,7-dihydro-5h-[1,2,4]triazolo[5,1-b][1,3]thiazin-6-ol Chemical compound S1CC(O)CN2N=C(C)N=C21 DPAYLXMDZVRDOT-UHFFFAOYSA-N 0.000 description 1
WPUAPGRZGJOIBX-UHFFFAOYSA-N 2-methylsulfanyl-8h-pyrido[2,3-d]pyrimidin-7-one Chemical compound C1=CC(=O)NC2=NC(SC)=NC=C21 WPUAPGRZGJOIBX-UHFFFAOYSA-N 0.000 description 1
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
DEMNOIPKWUBEAZ-UHFFFAOYSA-N 2-pyrimidin-5-ylethanol Chemical compound OCCC1=CN=CN=C1 DEMNOIPKWUBEAZ-UHFFFAOYSA-N 0.000 description 1
DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 1
HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
125000005917 3-methylpentyl group Chemical group 0.000 description 1
125000005925 3-methylpentyloxy group Chemical group 0.000 description 1
MGXJQAGOYXZWPI-HDICACEKSA-N 3-tert-butyl-1-[2-[4-[(3s,5r)-3,5-dimethylpiperazin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-yl]-1-ethylurea Chemical compound N=1C2=NC(N(C(=O)NC(C)(C)C)CC)=CC=C2C=NC=1NC(C=C1)=CC=C1N1C[C@H](C)N[C@H](C)C1 MGXJQAGOYXZWPI-HDICACEKSA-N 0.000 description 1
CEXNFABRKQBPBQ-UHFFFAOYSA-N 4-[4-[(5-acetyl-4-aminopyrimidin-2-yl)amino]phenyl]piperazine-1-carboxylic acid Chemical compound N1=C(N)C(C(=O)C)=CN=C1NC1=CC=C(N2CCN(CC2)C(O)=O)C=C1 CEXNFABRKQBPBQ-UHFFFAOYSA-N 0.000 description 1
JWOVNYMWNOVOCI-UHFFFAOYSA-N 4-[4-[(7-aminopyrido[2,3-d]pyrimidin-2-yl)amino]phenyl]piperazine-1-carboxylic acid Chemical compound N=1C2=NC(N)=CC=C2C=NC=1NC(C=C1)=CC=C1N1CCN(C(O)=O)CC1 JWOVNYMWNOVOCI-UHFFFAOYSA-N 0.000 description 1
WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 1
NYMDPDNETOLVBS-UHFFFAOYSA-N 4-fluoro-3-methylaniline Chemical compound CC1=CC(N)=CC=C1F NYMDPDNETOLVBS-UHFFFAOYSA-N 0.000 description 1
KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical group NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
KNWWGBNAUNTSRV-UHFFFAOYSA-N 4-methylpiperazine-1-carboxylic acid Chemical compound CN1CCN(C(O)=O)CC1 KNWWGBNAUNTSRV-UHFFFAOYSA-N 0.000 description 1
VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 1
XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
RJMLJXDTCAMXCD-UHFFFAOYSA-N 5-methyl-6h-pyrido[3,2-d]pyrimidin-7-amine Chemical compound C1=NC=C2N(C)CC(N)=CC2=N1 RJMLJXDTCAMXCD-UHFFFAOYSA-N 0.000 description 1
UDMMMWCGQGBXKV-UHFFFAOYSA-N 6,7-dichloro-2-methylsulfanylpyrido[2,3-d]pyrimidine Chemical compound C1=C(Cl)C(Cl)=NC2=NC(SC)=NC=C21 UDMMMWCGQGBXKV-UHFFFAOYSA-N 0.000 description 1
RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
FEDCSLRPQNWUHW-UHFFFAOYSA-N 6-bromo-2-methylsulfanyl-8h-pyrido[2,3-d]pyrimidin-7-one Chemical compound C1=C(Br)C(=O)NC2=NC(SC)=NC=C21 FEDCSLRPQNWUHW-UHFFFAOYSA-N 0.000 description 1
VTJAYEPEZVSVPT-UHFFFAOYSA-N 6-bromo-2-methylsulfinylpyrido[2,3-d]pyrimidin-7-amine Chemical compound C1=C(Br)C(N)=NC2=NC(S(=O)C)=NC=C21 VTJAYEPEZVSVPT-UHFFFAOYSA-N 0.000 description 1
DNYVNIZXYMXNJS-UHFFFAOYSA-N 6-bromo-7-chloro-2-methylsulfanylpyrido[2,3-d]pyrimidine Chemical compound C1=C(Br)C(Cl)=NC2=NC(SC)=NC=C21 DNYVNIZXYMXNJS-UHFFFAOYSA-N 0.000 description 1
GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 1
YXDOSGUYOPNXQU-UHFFFAOYSA-N 6-chloro-2-methylsulfanyl-8h-pyrido[2,3-d]pyrimidin-7-one Chemical compound C1=C(Cl)C(=O)NC2=NC(SC)=NC=C21 YXDOSGUYOPNXQU-UHFFFAOYSA-N 0.000 description 1
DWWCZKVBNWJJHC-UHFFFAOYSA-N 6-methoxy-2,3-dihydro-1h-indene-5-carbaldehyde Chemical compound C1=C(C=O)C(OC)=CC2=C1CCC2 DWWCZKVBNWJJHC-UHFFFAOYSA-N 0.000 description 1
TWTRRMSKLATOCF-UHFFFAOYSA-N 6-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-amine Chemical compound C1=C(C)C(N)=NC2=NC(SC)=NC=C21 TWTRRMSKLATOCF-UHFFFAOYSA-N 0.000 description 1
HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000003200 Adenoma Diseases 0.000 description 1
206010001233 Adenoma benign Diseases 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000167854 Bourreria succulenta Species 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
229940126657 Compound 17 Drugs 0.000 description 1
229940126639 Compound 33 Drugs 0.000 description 1
229940127007 Compound 39 Drugs 0.000 description 1
102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
208000007342 Diabetic Nephropathies Diseases 0.000 description 1
108060006698 EGF receptor Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
YSWHPLCDIMUKFE-QWRGUYRKSA-N Glu-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YSWHPLCDIMUKFE-QWRGUYRKSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000846416 Homo sapiens Fibroblast growth factor 1 Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
206010023347 Keratoacanthoma Diseases 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
NHJSWORVNIOXIT-UHFFFAOYSA-N PD-166866 Chemical compound COC1=CC(OC)=CC(C=2C(=NC3=NC(N)=NC=C3C=2)NC(=O)NC(C)(C)C)=C1 NHJSWORVNIOXIT-UHFFFAOYSA-N 0.000 description 1
108091008606 PDGF receptors Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241001494479 Pecora Species 0.000 description 1
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
108010076669 Proline-Directed Protein Kinases Proteins 0.000 description 1
102000011732 Proline-Directed Protein Kinases Human genes 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
239000007868 Raney catalyst Substances 0.000 description 1
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
229910000564 Raney nickel Inorganic materials 0.000 description 1
WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
201000010208 Seminoma Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
229940022663 acetate Drugs 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
208000030961 allergic reaction Diseases 0.000 description 1
BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
229950010817 alvocidib Drugs 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
150000001448 anilines Chemical class 0.000 description 1
125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
230000003527 anti-angiogenesis Effects 0.000 description 1
230000002788 anti-peptide Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
235000021311 artificial sweeteners Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
235000010290 biphenyl Nutrition 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
239000008004 cell lysis buffer Substances 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
229940081733 cetearyl alcohol Drugs 0.000 description 1
229940056318 ceteth-20 Drugs 0.000 description 1
239000013000 chemical inhibitor Substances 0.000 description 1
235000019693 cherries Nutrition 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
125000000068 chlorophenyl group Chemical group 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
210000000215 ciliated epithelial cell Anatomy 0.000 description 1
101150041757 cmk gene Proteins 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000004040 coloring Methods 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
229940126543 compound 14 Drugs 0.000 description 1
229940125758 compound 15 Drugs 0.000 description 1
229940126142 compound 16 Drugs 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
229940125810 compound 20 Drugs 0.000 description 1
229940126086 compound 21 Drugs 0.000 description 1
229940126208 compound 22 Drugs 0.000 description 1
229940125833 compound 23 Drugs 0.000 description 1
229940125961 compound 24 Drugs 0.000 description 1
229940125846 compound 25 Drugs 0.000 description 1
229940125851 compound 27 Drugs 0.000 description 1
229940127204 compound 29 Drugs 0.000 description 1
229940126214 compound 3 Drugs 0.000 description 1
229940125877 compound 31 Drugs 0.000 description 1
229940125878 compound 36 Drugs 0.000 description 1
229940125807 compound 37 Drugs 0.000 description 1
229940127573 compound 38 Drugs 0.000 description 1
229940126540 compound 41 Drugs 0.000 description 1
229940125936 compound 42 Drugs 0.000 description 1
229940125844 compound 46 Drugs 0.000 description 1
229940127271 compound 49 Drugs 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
229940126545 compound 53 Drugs 0.000 description 1
229940127113 compound 57 Drugs 0.000 description 1
229940125900 compound 59 Drugs 0.000 description 1
229940126179 compound 72 Drugs 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000012043 crude product Substances 0.000 description 1
229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
208000033679 diabetic kidney disease Diseases 0.000 description 1
125000005265 dialkylamine group Chemical group 0.000 description 1
150000004985 diamines Chemical class 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
239000013024 dilution buffer Substances 0.000 description 1
125000000532 dioxanyl group Chemical group 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000009510 drug design Methods 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
SIHZWGODIRRSRA-ONEGZZNKSA-N erbstatin Chemical compound OC1=CC=C(O)C(\C=C\NC=O)=C1 SIHZWGODIRRSRA-ONEGZZNKSA-N 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 1
FVPISMANESAJQZ-UHFFFAOYSA-N ethyl 2-diethoxyphosphoryl-2-fluoroacetate Chemical compound CCOC(=O)C(F)P(=O)(OCC)OCC FVPISMANESAJQZ-UHFFFAOYSA-N 0.000 description 1
GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
SNNHLSHDDGJVDM-UHFFFAOYSA-N ethyl 4-chloro-2-methylsulfanylpyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(SC)N=C1Cl SNNHLSHDDGJVDM-UHFFFAOYSA-N 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000010408 film Substances 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
229930003935 flavonoid Natural products 0.000 description 1
150000002215 flavonoids Chemical class 0.000 description 1
235000017173 flavonoids Nutrition 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000007789 gas Substances 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229940014259 gelatin Drugs 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
229940075529 glyceryl stearate Drugs 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
239000011630 iodine Substances 0.000 description 1
230000007794 irritation Effects 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
125000000468 ketone group Chemical group 0.000 description 1
229940099584 lactobionate Drugs 0.000 description 1
JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229940070765 laurate Drugs 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
239000000155 melt Substances 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
229960002900 methylcellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
229940045641 monobasic sodium phosphate Drugs 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
STUHQDIOZQUPGP-UHFFFAOYSA-N morpholin-4-ium-4-carboxylate Chemical compound OC(=O)N1CCOCC1 STUHQDIOZQUPGP-UHFFFAOYSA-N 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
JFCHSQDLLFJHOA-UHFFFAOYSA-N n,n-dimethylsulfamoyl chloride Chemical compound CN(C)S(Cl)(=O)=O JFCHSQDLLFJHOA-UHFFFAOYSA-N 0.000 description 1
APVPOHHVBBYQAV-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyloctadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 APVPOHHVBBYQAV-UHFFFAOYSA-N 0.000 description 1
CYSOBNVWOAGUIR-UHFFFAOYSA-N n-[6-bromo-2-[4-[2-(diethylamino)ethoxy]anilino]pyrido[2,3-d]pyrimidin-7-yl]acetamide;hydrochloride Chemical compound Cl.C1=CC(OCCN(CC)CC)=CC=C1NC1=NC=C(C=C(Br)C(NC(C)=O)=N2)C2=N1 CYSOBNVWOAGUIR-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
HACVAQDSDMVAMR-UHFFFAOYSA-N n-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-amine Chemical compound C1=NC(SC)=NC2=NC(NC)=CC=C21 HACVAQDSDMVAMR-UHFFFAOYSA-N 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
239000000025 natural resin Substances 0.000 description 1
235000021096 natural sweeteners Nutrition 0.000 description 1
IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
210000003739 neck Anatomy 0.000 description 1
230000035407 negative regulation of cell proliferation Effects 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
125000006574 non-aromatic ring group Chemical group 0.000 description 1
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
229940039748 oxalate Drugs 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
201000010198 papillary carcinoma Diseases 0.000 description 1
239000006201 parenteral dosage form Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
108010091212 pepstatin Proteins 0.000 description 1
229950000964 pepstatin Drugs 0.000 description 1
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
210000003800 pharynx Anatomy 0.000 description 1
125000005561 phenanthryl group Chemical group 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229940080469 phosphocellulose Drugs 0.000 description 1
230000000865 phosphorylative effect Effects 0.000 description 1
125000005545 phthalimidyl group Chemical group 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
125000005936 piperidyl group Chemical group 0.000 description 1
229960005235 piperonyl butoxide Drugs 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920006254 polymer film Polymers 0.000 description 1
229920000131 polyvinylidene Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
159000000018 pyrido[2,3-d]pyrimidines Chemical class 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
229940048084 pyrophosphate Drugs 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000022983 regulation of cell cycle Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
239000010802 sludge Substances 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
229940032147 starch Drugs 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
125000005017 substituted alkenyl group Chemical group 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000000057 synthetic resin Substances 0.000 description 1
229920003002 synthetic resin Polymers 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000007885 tablet disintegrant Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
QESQUIMEUZZKIO-KDURUIRLSA-N tert-butyl (2s,6r)-4-[4-[[7-(tert-butylcarbamoylamino)pyrido[2,3-d]pyrimidin-2-yl]amino]phenyl]-2,6-dimethylpiperazine-1-carboxylate Chemical compound C1[C@@H](C)N(C(=O)OC(C)(C)C)[C@@H](C)CN1C(C=C1)=CC=C1NC1=NC=C(C=CC(NC(=O)NC(C)(C)C)=N2)C2=N1 QESQUIMEUZZKIO-KDURUIRLSA-N 0.000 description 1
ZLOWQQWAHOEBKP-UHFFFAOYSA-N tert-butyl 2,2-dimethyl-4-(4-nitrophenyl)piperazine-1-carboxylate Chemical compound C1C(C)(C)N(C(=O)OC(C)(C)C)CCN1C1=CC=C([N+]([O-])=O)C=C1 ZLOWQQWAHOEBKP-UHFFFAOYSA-N 0.000 description 1
UOUFRTFWWBCVPV-UHFFFAOYSA-N tert-butyl 4-(2,4-dioxo-1H-thieno[3,2-d]pyrimidin-3-yl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CC1)n1c(=O)[nH]c2ccsc2c1=O UOUFRTFWWBCVPV-UHFFFAOYSA-N 0.000 description 1
UYFBIPVOSCMPAT-UHFFFAOYSA-N tert-butyl 4-[4-[(7-aminopyrido[2,3-d]pyrimidin-2-yl)amino]phenyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C=CC(N)=N2)C2=N1 UYFBIPVOSCMPAT-UHFFFAOYSA-N 0.000 description 1
CBNUMRNHDJPEFG-UHFFFAOYSA-N tert-butyl 4-[4-[7-[cyclohexylcarbamoyl(methyl)amino]pyrido[2,3-d]pyrimidin-2-yl]phenyl]piperazine-1-carboxylate Chemical compound C=1C=C2C=NC(C=3C=CC(=CC=3)N3CCN(CC3)C(=O)OC(C)(C)C)=NC2=NC=1N(C)C(=O)NC1CCCCC1 CBNUMRNHDJPEFG-UHFFFAOYSA-N 0.000 description 1
YYQUQHCUSHLDGL-UHFFFAOYSA-N tert-butyl 4-[4-[[6-bromo-7-(methylcarbamoylamino)pyrido[2,3-d]pyrimidin-2-yl]amino]phenyl]piperazine-1-carboxylate Chemical compound N=1C=C2C=C(Br)C(NC(=O)NC)=NC2=NC=1NC(C=C1)=CC=C1N1CCN(C(=O)OC(C)(C)C)CC1 YYQUQHCUSHLDGL-UHFFFAOYSA-N 0.000 description 1
TXQNFPMJJVZLHW-UHFFFAOYSA-N tert-butyl 4-[4-[[7-(propan-2-ylcarbamoylamino)pyrido[2,3-d]pyrimidin-2-yl]amino]phenyl]piperazine-1-carboxylate Chemical compound N=1C2=NC(NC(=O)NC(C)C)=CC=C2C=NC=1NC(C=C1)=CC=C1N1CCN(C(=O)OC(C)(C)C)CC1 TXQNFPMJJVZLHW-UHFFFAOYSA-N 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
125000003944 tolyl group Chemical group 0.000 description 1
210000002105 tongue Anatomy 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
125000004665 trialkylsilyl group Chemical group 0.000 description 1
IIHPVYJPDKJYOU-UHFFFAOYSA-N triphenylcarbethoxymethylenephosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OCC)C1=CC=CC=C1 IIHPVYJPDKJYOU-UHFFFAOYSA-N 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
208000010576 undifferentiated carcinoma Diseases 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
150000003672 ureas Chemical class 0.000 description 1
229940070710 valerate Drugs 0.000 description 1
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
239000011345 viscous material Substances 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1
229910000166 zirconium phosphate Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Enzymes And Modification Thereof (AREA)

BG106850A 2000-01-25 2002-06-20 ПИРИДО [2,3-d] ПИРИМИДИН - 2,7 - ДИАМИН КИНАЗА ИНХИБИТОРИ BG106850A (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US17826100P	2000-01-25	2000-01-25
PCT/IB2001/000069 WO2001055147A1 (en)	2000-01-25	2001-01-23	PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS

Publications (1)

Publication Number	Publication Date
BG106850A true BG106850A (bg)	2003-02-28

Family

ID=22651853

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG106850A BG106850A (bg)	2000-01-25	2002-06-20	ПИРИДО [2,3-d] ПИРИМИДИН - 2,7 - ДИАМИН КИНАЗА ИНХИБИТОРИ

Country Status (34)

Country	Link
EP (1)	EP1254137A1 (pl)
JP (1)	JP4047010B2 (pl)
KR (1)	KR20020065939A (pl)
CN (1)	CN1395578A (pl)
AP (1)	AP2002002586A0 (pl)
AR (1)	AR030044A1 (pl)
AU (1)	AU2542501A (pl)
BG (1)	BG106850A (pl)
BR (1)	BR0107751A (pl)
CA (1)	CA2397961C (pl)
CO (1)	CO5261549A1 (pl)
CR (1)	CR6706A (pl)
CZ (1)	CZ20022475A3 (pl)
DZ (1)	DZ3266A1 (pl)
EA (1)	EA200200643A1 (pl)
EE (1)	EE200200405A (pl)
GT (1)	GT200100016A (pl)
HN (1)	HN2001000013A (pl)
HU (1)	HUP0204141A3 (pl)
IL (1)	IL150545A0 (pl)
IS (1)	IS6443A (pl)
MA (1)	MA26868A1 (pl)
MX (1)	MXPA02007221A (pl)
NO (1)	NO20023527L (pl)
OA (1)	OA12161A (pl)
PA (1)	PA8510701A1 (pl)
PE (1)	PE20011066A1 (pl)
PL (1)	PL356802A1 (pl)
SK (1)	SK10632002A3 (pl)
SV (1)	SV2002000294A (pl)
TN (1)	TNSN01014A1 (pl)
WO (1)	WO2001055147A1 (pl)
YU (1)	YU50402A (pl)
ZA (1)	ZA200205879B (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7235551B2 (en)	2000-03-02	2007-06-26	Smithkline Beecham Corporation	1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
ATE521353T1 (de)	2000-10-23	2011-09-15	Glaxosmithkline Llc	Neues trisubstitutiertes 8h-pyridoä2,3- düpyrimidin-7-onderivat zur behandlung von durch csbp/p38kinase vermittelten krankheiten
PE20030008A1 (es) *	2001-06-19	2003-01-22	Bristol Myers Squibb Co	Inhibidores duales de pde 7 y pde 4
KR20040103972A (ko)	2002-04-19	2004-12-09	스미스클라인 비참 코포레이션	신규 화합물
BR0316680A (pt) *	2002-11-28	2005-10-18	Schering Ag	Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos
US7157455B2 (en) *	2003-02-10	2007-01-02	Hoffmann-La Roche Inc.	4-Aminopyrimidine-5-one derivatives
TW200502236A (en)	2003-03-28	2005-01-16	Hoffmann La Roche	Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
FR2873118B1 (fr)	2004-07-15	2007-11-23	Sanofi Synthelabo	Derives de pyrido-pyrimidine, leur application en therapeutique
CN101014600A (zh) *	2004-09-21	2007-08-08	霍夫曼-拉罗奇有限公司	用作蛋白激酶抑制剂的6－(2－烷基－苯基)－吡啶并[2,3－d]嘧啶类
UY29439A1 (es)	2005-03-25	2006-10-02	Glaxo Group Ltd	Nuevos compuestos
UY29440A1 (es)	2005-03-25	2006-10-02	Glaxo Group Ltd	Nuevos compuestos
EP1865959A2 (en)	2005-03-25	2007-12-19	Glaxo Group Limited	Process for preparing pyridoý2,3-d¨pyrimidin-7-one and 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one derivatives
WO2006110298A2 (en)	2005-03-25	2006-10-19	Glaxo Group Limited	8-alkyl/aryl-4-aryl-2-n- (alkylamino)-n'-substituted-n'-cyanoguanidino-8h-pyrido[2,3-d]pyrimidin-7-one compounds and use thereof
FR2887882B1 (fr)	2005-07-01	2007-09-07	Sanofi Aventis Sa	Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
WO2007009911A1 (en) *	2005-07-21	2007-01-25	F. Hoffmann-La Roche Ag	PYRIDO [2 , 3-D] PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS
ATE482958T1 (de) *	2005-08-09	2010-10-15	Irm Llc	Verbindungen und zusammensetzungen als proteinkinaseinhibitoren
FR2896246B1 (fr)	2006-01-13	2008-08-15	Sanofi Aventis Sa	Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
EP1914234A1 (en)	2006-10-16	2008-04-23	GPC Biotech Inc.	Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
JO2985B1 (ar)	2006-12-20	2016-09-05	Takeda Pharmaceuticals Co	مثبطات كينازmapk/erk
FR2910813B1 (fr)	2006-12-28	2009-02-06	Sanofi Aventis Sa	Nouvelle utilisation therapeutique pour le traitement des leucemies
EP2112150B1 (en)	2008-04-22	2013-10-16	Forma Therapeutics, Inc.	Improved raf inhibitors
WO2010063352A1 (en) *	2008-12-01	2010-06-10	Merck Patent Gmbh	2, 5-diamino-substituted pyrido [4, 3-d] pyrimidines as autotaxin inhibitors against cancer
GB201104267D0 (en)	2011-03-14	2011-04-27	Cancer Rec Tech Ltd	Pyrrolopyridineamino derivatives
GB201216017D0 (en)	2012-09-07	2012-10-24	Cancer Rec Tech Ltd	Inhibitor compounds
GB201216018D0 (en)	2012-09-07	2012-10-24	Cancer Rec Tech Ltd	Pharmacologically active compounds
WO2014151682A1 (en)	2013-03-14	2014-09-25	Icahn School Of Medicine At Mount Sinai	Pyrimidine compounds as kinase inhibitors
GB201403536D0 (en)	2014-02-28	2014-04-16	Cancer Rec Tech Ltd	Inhibitor compounds
KR101671404B1 (ko) *	2014-09-02	2016-11-02	한국원자력의학원	항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도
CN107286180B (zh) *	2016-04-11	2019-07-02	上海勋和医药科技有限公司	杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
GB201709840D0 (en)	2017-06-20	2017-08-02	Inst Of Cancer Research: Royal Cancer Hospital	Methods and medical uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL115256A0 (en) *	1994-11-14	1995-12-31	Warner Lambert Co	6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
HUT76853A (en) *	1994-11-14	1997-12-29	Warner Lambert Co	6-aryl pyrido[2,3-d]pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation and pharmaceutical compositions containing the same
US5620981A (en) *	1995-05-03	1997-04-15	Warner-Lambert Company	Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
AU763839B2 (en) *	1998-05-26	2003-07-31	Warner-Lambert Company	Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation

2001
- 2001-01-23 CZ CZ20022475A patent/CZ20022475A3/cs unknown
- 2001-01-23 HU HU0204141A patent/HUP0204141A3/hu unknown
- 2001-01-23 PL PL01356802A patent/PL356802A1/pl not_active Application Discontinuation
- 2001-01-23 EA EA200200643A patent/EA200200643A1/ru unknown
- 2001-01-23 PA PA20018510701A patent/PA8510701A1/es unknown
- 2001-01-23 GT GT200100016A patent/GT200100016A/es unknown
- 2001-01-23 PE PE2001000072A patent/PE20011066A1/es not_active Application Discontinuation
- 2001-01-23 DZ DZ013266A patent/DZ3266A1/fr active
- 2001-01-23 YU YU50402A patent/YU50402A/sh unknown
- 2001-01-23 MX MXPA02007221A patent/MXPA02007221A/es not_active Application Discontinuation
- 2001-01-23 AU AU25425/01A patent/AU2542501A/en not_active Abandoned
- 2001-01-23 EE EEP200200405A patent/EE200200405A/xx unknown
- 2001-01-23 OA OA1200200213A patent/OA12161A/en unknown
- 2001-01-23 BR BR0107751-1A patent/BR0107751A/pt not_active IP Right Cessation
- 2001-01-23 SK SK1063-2002A patent/SK10632002A3/sk not_active Application Discontinuation
- 2001-01-23 JP JP2001561006A patent/JP4047010B2/ja not_active Expired - Fee Related
- 2001-01-23 CN CN01804048A patent/CN1395578A/zh active Pending
- 2001-01-23 CA CA002397961A patent/CA2397961C/en not_active Expired - Fee Related
- 2001-01-23 WO PCT/IB2001/000069 patent/WO2001055147A1/en not_active Ceased
- 2001-01-23 IL IL15054501A patent/IL150545A0/xx unknown
- 2001-01-23 AR ARP010100285A patent/AR030044A1/es not_active Application Discontinuation
- 2001-01-23 EP EP01900591A patent/EP1254137A1/en not_active Withdrawn
- 2001-01-23 KR KR1020027009516A patent/KR20020065939A/ko not_active Ceased
- 2001-01-23 AP APAP/P/2002/002586A patent/AP2002002586A0/en unknown
- 2001-01-24 TN TNTNSN01014A patent/TNSN01014A1/fr unknown
- 2001-01-24 CO CO01005268A patent/CO5261549A1/es not_active Application Discontinuation
- 2001-01-24 HN HN2001000013A patent/HN2001000013A/es unknown
- 2001-01-24 SV SV2001000294A patent/SV2002000294A/es not_active Application Discontinuation
2002
- 2002-06-20 BG BG106850A patent/BG106850A/bg unknown
- 2002-06-25 IS IS6443A patent/IS6443A/is unknown
- 2002-07-17 CR CR6706A patent/CR6706A/es not_active Application Discontinuation
- 2002-07-22 MA MA26736A patent/MA26868A1/fr unknown
- 2002-07-23 ZA ZA200205879A patent/ZA200205879B/en unknown
- 2002-07-24 NO NO20023527A patent/NO20023527L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2397961C (en)	2008-08-26
CZ20022475A3 (cs)	2003-03-12
JP4047010B2 (ja)	2008-02-13
NO20023527D0 (no)	2002-07-24
IS6443A (is)	2002-06-25
CO5261549A1 (es)	2003-03-31
MXPA02007221A (es)	2002-11-29
SV2002000294A (es)	2002-07-16
ZA200205879B (en)	2003-09-29
MA26868A1 (fr)	2004-12-20
CR6706A (es)	2005-04-04
NO20023527L (no)	2002-09-10
TNSN01014A1 (fr)	2005-11-10
BR0107751A (pt)	2002-11-12
PA8510701A1 (es)	2002-12-11
HUP0204141A3 (en)	2005-03-29
OA12161A (en)	2006-05-08
HN2001000013A (es)	2001-06-18
EA200200643A1 (ru)	2002-12-26
PE20011066A1 (es)	2001-10-22
AU2542501A (en)	2001-08-07
SK10632002A3 (sk)	2003-06-03
CA2397961A1 (en)	2001-08-02
HUP0204141A2 (hu)	2003-04-28
KR20020065939A (ko)	2002-08-14
EE200200405A (et)	2003-12-15
AR030044A1 (es)	2003-08-13
IL150545A0 (en)	2003-02-12
CN1395578A (zh)	2003-02-05
EP1254137A1 (en)	2002-11-06
PL356802A1 (pl)	2004-07-12
JP2003523357A (ja)	2003-08-05
WO2001055147A1 (en)	2001-08-02
DZ3266A1 (fr)	2001-08-02
AP2002002586A0 (en)	2002-09-30
YU50402A (sh)	2005-11-28
GT200100016A (es)	2001-10-19

Publication	Publication Date	Title
BG106850A (bg)	2003-02-28	ПИРИДО [2,3-d] ПИРИМИДИН - 2,7 - ДИАМИН КИНАЗА ИНХИБИТОРИ
US7053070B2 (en)	2006-05-30	Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
CA2636701C (en)	2014-08-05	Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors
JP5941513B2 (ja)	2016-06-29	Ｂｃｒ−ａｂｌの低分子のミリスチン酸エステル阻害剤及びその使用方法
JP3965439B2 (ja)	2007-08-29	上皮増殖因子受容体ファミリーのチロシンキナーゼを阻害することができる三環式化合物
AU2004260689B8 (en)	2008-05-15	Compounds and compositions as protein kinase inhibitors
AU2004279427B2 (en)	2008-07-03	Compounds and compositions as protein kinase inhibitors
JP5134548B2 (ja)	2013-01-30	過剰増殖性疾患の処置のためのＥｒｂＢＩ型受容体チロシンキナーゼ阻害剤としてのＮ４−フェニルキナゾリン−４−アミン誘導体および関連化合物
US20040242600A1 (en)	2004-12-02	4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
EP1080092A2 (en)	2001-03-07	Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
AU2007254491A1 (en)	2007-11-29	Compositions and methods for FGF receptor kinases inhibitors
SK141097A3 (en)	1998-07-08	Pyrido[2,3-d]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
RO117257B1 (ro)	2001-12-28	Derivati pirimidinici biciclici, capabili sa inhibe receptorii de tirozin kinaza ai factorului de crestere epidermic, compozitie farmaceutica care ii contine si metoda de inhibare a receptorilor de tirozin kinaza
JP2010521506A (ja)	2010-06-24	置換イミダゾおよびトリアゾロピリミジン類
US7323469B2 (en)	2008-01-29	7H-pyrrolo[2,3-d]pyrimidine derivatives